Aligos Therapeutics Funding & Investors
South San Francisco, CA
Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases. Aligos is focused on the development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). Aligos’ strategy is to harness the deep expertise and decades of drug development experience its workforce has in liver disease, particularly viral hepatitis, to rapidly advance its pipeline of potentially best-in-class molecules.
aligos.comTotal Amount Raised: $317,000,000
Aligos Therapeutics Funding Rounds
Post Ipo Equity
$92,000,000
Post Ipo Equity Investors
Roche Venture FundLawrence BlattArmistice CapitalEcoR1 CapitalDeep Track CapitalSeries B
$125,000,000
Series B Investors
Wellington ManagementCormorant Asset ManagementBoxer CapitalHenderson Global InvestorsPivotal bioVenture Partners Investment AdvisorLogos CapitalVersant VenturesRoche Venture FundNovo HoldingsVivo CapitalIPO
Unknown
Series A
$100,000,000
Series A Investors
Versant VenturesNovo HoldingsRoche Venture FundVivo Capital